JP4672368B2 - 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 - Google Patents

副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 Download PDF

Info

Publication number
JP4672368B2
JP4672368B2 JP2004544592A JP2004544592A JP4672368B2 JP 4672368 B2 JP4672368 B2 JP 4672368B2 JP 2004544592 A JP2004544592 A JP 2004544592A JP 2004544592 A JP2004544592 A JP 2004544592A JP 4672368 B2 JP4672368 B2 JP 4672368B2
Authority
JP
Japan
Prior art keywords
treatment
formula
hydrogen
lower alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004544592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504751A (ja
JP2006504751A5 (fr
Inventor
ユージーン・エイ・ウォルタリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University and Agricultural and Mechanical College
Original Assignee
Louisiana State University and Agricultural and Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University and Agricultural and Mechanical College filed Critical Louisiana State University and Agricultural and Mechanical College
Publication of JP2006504751A publication Critical patent/JP2006504751A/ja
Publication of JP2006504751A5 publication Critical patent/JP2006504751A5/ja
Application granted granted Critical
Publication of JP4672368B2 publication Critical patent/JP4672368B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2004544592A 2002-10-15 2003-10-13 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 Expired - Fee Related JP4672368B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (fr) 2002-10-15 2003-10-13 Utilisation de derives d'epothilone pour le traitement de l'hyperparathyroidie

Publications (3)

Publication Number Publication Date
JP2006504751A JP2006504751A (ja) 2006-02-09
JP2006504751A5 JP2006504751A5 (fr) 2006-11-30
JP4672368B2 true JP4672368B2 (ja) 2011-04-20

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544592A Expired - Fee Related JP4672368B2 (ja) 2002-10-15 2003-10-13 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用

Country Status (16)

Country Link
US (2) US20060142354A1 (fr)
EP (1) EP1553938B1 (fr)
JP (1) JP4672368B2 (fr)
CN (1) CN1297269C (fr)
AT (1) ATE350034T1 (fr)
AU (1) AU2003267751A1 (fr)
BR (1) BR0315293A (fr)
CA (1) CA2501717C (fr)
CY (1) CY1106385T1 (fr)
DE (1) DE60310975T2 (fr)
DK (1) DK1553938T3 (fr)
ES (1) ES2279139T3 (fr)
HK (1) HK1080768A1 (fr)
PT (1) PT1553938E (fr)
SI (1) SI1553938T1 (fr)
WO (1) WO2004035050A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504474A (ja) * 1996-11-18 2001-04-03 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
JP2002502810A (ja) * 1998-02-05 2002-01-29 ノバルティス アクチエンゲゼルシャフト エポシロン組成物
US20020119202A1 (en) * 1993-07-19 2002-08-29 Hunter William L. Anti-angiogenic compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119202A1 (en) * 1993-07-19 2002-08-29 Hunter William L. Anti-angiogenic compositions and methods of use
JP2001504474A (ja) * 1996-11-18 2001-04-03 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
JP2002502810A (ja) * 1998-02-05 2002-01-29 ノバルティス アクチエンゲゼルシャフト エポシロン組成物

Also Published As

Publication number Publication date
CA2501717A1 (fr) 2004-04-29
CN1297269C (zh) 2007-01-31
US20110152329A1 (en) 2011-06-23
JP2006504751A (ja) 2006-02-09
CY1106385T1 (el) 2011-10-12
HK1080768A1 (en) 2006-05-04
CA2501717C (fr) 2012-09-18
SI1553938T1 (sl) 2007-06-30
AU2003267751A1 (en) 2004-05-04
EP1553938B1 (fr) 2007-01-03
ATE350034T1 (de) 2007-01-15
DE60310975T2 (de) 2007-07-12
BR0315293A (pt) 2005-08-30
DE60310975D1 (de) 2007-02-15
EP1553938A1 (fr) 2005-07-20
ES2279139T3 (es) 2007-08-16
WO2004035050A1 (fr) 2004-04-29
CN1703217A (zh) 2005-11-30
PT1553938E (pt) 2007-03-30
US20060142354A1 (en) 2006-06-29
DK1553938T3 (da) 2007-03-26

Similar Documents

Publication Publication Date Title
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP2006176542A (ja) フェニルエテンスルホンアミド誘導体含有医薬
US20040146498A1 (en) Pharmaceutical combinations
AU2002305952A1 (en) Pharmaceutical combinations
US20090246172A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
JP2016179994A (ja) イネカルシトールの新しい治療的使用
CN1356908A (zh) 包含低分子量凝血酶抑制剂及其药物前体的药用制剂
WO2009104149A1 (fr) Combinaison comprenant du paclitaxel destinée au traitement du cancer des ovaires
KR20040106422A (ko) 간암 및 다른 암 질병 치료용 에포틸론 유도체
JP2020520374A (ja) 関節リウマチの治療用組成物および治療方法
JP4672368B2 (ja) 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用
JPWO2004096230A1 (ja) 関節リウマチ治療剤
AU2003223958B2 (en) Combinations comprising epothilone derivatives and alkylating agents
AU2002366531B2 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
JP2004250441A (ja) 血小板大凝集塊の形成阻害剤
WO2009104152A1 (fr) Traitement combiné du cancer des ovaires
JP2000086519A (ja) 抗リウマチ薬効果増強剤
JPH06183978A (ja) 血小板凝集抑制組成物
WO2009104150A1 (fr) Combinaison comprenant du bosentane destinée au traitement du cancer des ovaires

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110119

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees